NEW YORK--(BUSINESS WIRE)--Noom for Work, Noom’s digital enterprise unit, announced the expansion of its offering to include access to Noom Med, a clinical obesity management solution. With growing employee and member demand for obesity support and anti-obesity medications, the commercial offering for Noom Med provides access to not only its personalized psychological tools, community, and content, but also to clinicians with obesity care training who deliver customized plans to optimize weight loss goals.

纽约-（商业线）-Noom数字企业部门的工作人员Noom宣布扩大其产品范围，以包括获得临床肥胖管理解决方案Noom Med。随着员工和会员对肥胖支持和抗肥胖药物需求的不断增长，Noom Med的商业产品不仅可以访问其个性化的心理工具，社区和内容，还可以访问具有肥胖护理培训的临床医生，他们提供定制计划以优化减肥目标。

True to Noom’s industry-leading behavior change capabilities, Noom Med also supports patients who are seeking to reduce reliance on GLP-1 medications to maintain health outcomes without medical assistance..

对于Noom领先的行业行为改变能力，Noom Med还支持寻求减少对GLP-1药物依赖的患者，以便在没有医疗帮助的情况下维持健康结果。。

How Noom Med Works

Noom Med如何工作

Noom Med is accessible to patients with a BMI of 30 or higher or greater than or equal to 27 with one or more weight-related medical conditions. Patients receive a health evaluation by a board-certified physician or a physician-supervised nurse practitioner, and complete comprehensive lab work. A clinician works with the patient via video visit to create an individualized care plan specific to the patient’s biology, concerns, and overall health goals.

BMI为30或更高或大于或等于27且患有一种或多种体重相关疾病的患者可以使用Noom Med。患者接受董事会认证的医师或医师监督的执业护士的健康评估，并完成全面的实验室工作。临床医生通过视频访问与患者合作，创建针对患者生物学，关注点和整体健康目标的个性化护理计划。

Noom Med follows strict, physician-created protocols, and only patients who are clinically appropriate are prescribed medication. The complete plan is then delivered through Noom’s best-in-class mobile app, complete with interactive patient education, a psychology-based curriculum, and a suite of comprehensive nutrition and exercise tools.

Noom Med遵循严格的，由医生创建的方案，只有临床上合适的患者才能开处方药。然后通过Noom一流的移动app提供完整的计划，完成交互式患者教育，基于心理学的课程以及一套全面的营养和锻炼工具。

Once patients achieve their weight goals, they can then begin the process of weaning off medication to continue maintaining weight loss via newly-learned habits and behaviors..

一旦患者达到体重目标，他们就可以开始断奶药物的过程，通过新学到的习惯和行为继续保持体重减轻。。

“Weight maintenance is entirely possible even though current data shows weight regain may occur once stopping a GLP-1,” said Noom’s Chief of Medicine, Linda Anegawa, MD, MS, FACP, a physician board certified in Obesity Medicine and Internal Medicine. “Medications alone won’t power maintenance; only sustained lifestyle changes will drive the long-term improvements in craving pathways along with improvements in insulin resistance that comes with combined use of GLP-1s and behavioral interventions.

Noom的医学主任Linda Anegawa，医学博士，硕士，FACP是一家获得肥胖医学和内科医学认证的医师委员会，他说：“即使目前的数据显示，一旦停止GLP-1，体重可能会恢复，体重维持也是完全可能的。“仅靠药物不能维持治疗；只有持续的生活方式改变才能推动渴望途径的长期改善，同时结合使用GLP-1和行为干预措施改善胰岛素抵抗。

Together, these can literally rewire the brain over time.”.

一起，这些可以随着时间的推移重新连接大脑。”。

Critical Cost Management

关键成本管理

For those patients receiving GLP-1 medication, the costs of covering their treatment can be high — as much as $1,500 per employee/member, per month — adding millions of dollars in costs to employers and payers. The demand for this treatment is enormous and will continue — Morning Consult reported that five in 10 U.S.

对于那些接受GLP-1药物治疗的患者，治疗费用可能很高-每个员工/成员每月高达1500美元-为雇主和付款人增加数百万美元的费用。这种治疗的需求是巨大的，并将继续-早晨咨询报告说，五分之十的美国。

adults who have heard of GLP-1s are interested in trying them1, and according to HR Executive, if just half of those eligible were to seek out GLP-1s for weight loss, it would increase total costs for employers/payers to $840 per employee/member per year2..

听说过GLP-1的成年人有兴趣尝试它们1，根据人力资源执行官的说法，如果只有一半符合条件的人寻求GLP-1减肥，那么雇主/付款人的总费用将增加到每位840美元员工/会员每年2。。

“Nearly half of the working population will suffer from obesity by 2030, and with that comes a tsunami of costs to employers and payers — not just from GLP-1s, but the costs associated with other chronic conditions that come with weight gain,” said Geoff Cook, CEO of Noom. “These costs are simply unsustainable.

“到2030年，将近一半的工作人口将患上肥胖症，随之而来的是雇主和付款人的成本海啸-不仅仅来自GLP-1，还包括与体重增加相关的其他慢性病相关成本，”Noom首席执行官Geoff Cook说。“这些成本根本不可持续。

We’ve heard loud and clear the demand for a holistic solution that offers not only medical treatment for those with obesity, but also the behavioral change necessary to enable tapering of the medication to reverse the trends in weight gain in a sustainable, cost-effective way.”.

我们已经听到响亮而清晰地表达了对整体解决方案的需求，该解决方案不仅为肥胖者提供医疗服务，而且还提供必要的行为改变，以使药物逐渐减少，以可持续，经济的方式扭转体重增加的趋势方式“。

Noom Med ensures employers and payers are able to optimize outcomes at an affordable cost via:

Noom Med通过以下方式确保雇主和付款人能够以可承受的成本优化成果：

A stepped care model: Noom’s unique care model pairs a broad spectrum of care with personalized support that’s tailored to each member’s unique biology and lifestyle. Members are guided to the right care at the right time — only stepping up to medication to match the appropriate level of investment for the best health outcome..

分阶段护理模式：Noom独特的护理模式将广泛的护理与个性化支持相结合，专为每位会员独特的生物学和生活方式量身定制。成员在正确的时间被引导到正确的护理-只有加强药物治疗，以匹配适当的投资水平，以获得最佳的健康结果。。

A world-class behavior change curriculum: Our psychology-based program has guided millions toward healthy, lasting habits. 42% of members with obesity who lost at least 10% of their body weight kept it off for two years after using Noom.

世界一流的行为改变课程：我们基于心理学的课程引导数百万人走向健康，持久的习惯。42%的肥胖成员体重减轻了至少10%，在使用Noom后两年内保持不变。

Performance-based pricing based on outcomes that matter, including initial weight lost and maintained weight loss after medication.

基于绩效的定价基于重要的结果，包括初始体重减轻和服药后保持体重减轻。

A Complete Metabolic Solution for Total Population Health

一个完整的人口健康代谢解决方案

By adding Noom Med to the Noom for Work portfolio, employers and payers now have access to a comprehensive and customizable solution to address the nearly 75% of adults with pre-obesity or obesity. And the power of Noom’s brand awareness ensures strong employee adoption, which averages 25%, and for some employers as high as 80%..

通过将Noom Med添加到工作组合的Noom中，雇主和付款人现在可以获得全面和可定制的解决方案，以解决近75%的肥胖或肥胖成年人。Noom品牌意识的强大功能确保了员工的强烈采用，平均为25%，一些雇主高达80%。。

Cook summarized, “Noom delivers a unique offering that no other company can match — a proven behavior change program that can go beyond weight loss to the treatment of obesity and long-term weight maintenance, independent of medical assistance, to truly reverse the obesity trend in the US and relieve the downward cost pressures our clients face today.”.

库克总结说：“Noom提供了一种独特的服务，没有其他公司可以匹配-一种经过验证的行为改变计划，可以超越减肥，治疗肥胖和长期维持体重，独立于医疗援助，真正扭转肥胖美国的趋势，减轻客户今天面临的成本下降压力“。

To learn more about Noom Med for organizations and Noom for Work’s complete metabolic health offering, visit www.noom.com/for-work.

要了解更多关于Noom Med for Organisms和Noom for Work的完整代谢健康服务，请访问www.Noom.com/for-Work。

About Noom

大约下午

Noom is a digital healthcare company that connects people to content, coaching, community, and clinicians to build healthy habits and promote better living. The company has been awarded multiple grants from the National Institutes of Health and was the first mobile application to be recognized by the Centers for Disease Control and Prevention as a certified diabetes prevention program.

Noom是一家数字医疗保健公司，将人们与内容，辅导，社区和临床医生联系起来，以建立健康的习惯并促进更好的生活。该公司已获得美国国立卫生研究院的多项资助，是第一个被疾病控制和预防中心认可为认证糖尿病预防计划的移动应用程序。

Headquartered in New York City, Noom has been named one of Inc.’s Best Places to Work, Quartz’s Best Workplaces for Remote Workers, and Fortune’s Best Workplaces in Technology..

Noom总部设在纽约市，被评为Inc.最好的工作场所之一，石英是远程工人最好的工作场所，Fortune是科技最好的工作场所。。

1 Moquin, E. (2023, May 8). Ozempic Piques Interest of Nearly 3 in 10 Consumers. Morning Consult Pro. Retrieved October 6, 2023, from https://pro.morningconsult.com/analysis/ozempic-wegovy-mounjaro-weight-loss-drugs

1 Moquin，E。（2023年5月8日）。Ozempic在10个消费者中有近3个兴趣。早上咨询专业。检索2023年10月6日https://pro.morningconsult.com/analysis/ozempic-wegovy-mounjaro-weight-loss-drugs

2 Becker, S., & Midlam, C. (2023, May 26). New anti-obesity drugs represent challenge, opportunity for employers. HR Executive. Retrieved October 6, 2023, from https://hrexecutive.com/new-anti-obesity-drugs-represent-challenge-opportunity-for-employers/

2 Becker，S。和Midlam，C。（2023年5月26日）。新的抗肥胖药物为雇主带来了挑战和机会。人力资源执行官。检索2023年10月6日https://hrexecutive.com/new-anti-obesity-drugs-represent-challenge-opportunity-for-employers/